| Drug Name |
Sonidegib |
| Drug ID |
BADD_D02472 |
| Description |
Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. |
| Indications and Usage |
Sonidegib is approved for use in the US and EU for treatment of adults with locally advanced basal cell carcinoma (BCC) that has recurred post surgery or radiation therapy. It is also approved for adult patients with BCC who are not eligible for surgery or radiation therapy. (2) |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XJ02 |
| DrugBank ID |
DB09143
|
| KEGG ID |
D10119
|
| MeSH ID |
C561435
|
| PubChem ID |
24775005
|
| TTD Drug ID |
D09BNZ
|
| NDC Product Code |
47335-303 |
| UNII |
0RLU3VTK5M
|
| Synonyms |
sonidegib | (1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- methyl-4'-(trifluoromethoxy)-, rel- | Odomzo | N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl-3-carboxamide | LDE225 | NVP-LDE225 |
